Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 48,413	$ 169,681
Marketable securities	208,363
Prepaid expenses and other current assets	1,423	1,677
Total current assets	258,199	171,358
Long-term assets
Property and equipment, net	196	12
Operating lease right-of-use assets	2,992	407
Intangible assets, net	7,291	8,749
Long-term marketable securities	27,945
Other long-term assets	83	165
Total assets	296,706	180,691
Current liabilities
Accounts payable	6,243	3,149
Accrued compensation	3,408	3,135
Accrued clinical trial site costs	1,762	3,393
Operating lease liabilities	448	273
Other current liabilities	3,101	1,555
Total current liabilities	14,962	11,505
Long-term liabilities
Contingent liability for Essentialis purchase price	14,464	11,549
Long-term lease liabilities	2,581	130
Total liabilities	32,007	23,184
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 41,041,216 and 31,678,159 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	41	32
Additional paid-in-capital	660,041	433,885
Accumulated other comprehensive gain	895
Accumulated deficit	(396,278)	(276,410)
Total stockholders’ equity	264,699	157,507
Total liabilities and stockholders’ equity	$ 296,706	$ 180,691